Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
3.
Oncogene ; 21(22): 3611-9, 2002 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-12032863

RESUMO

Apo2L/TRAIL exhibits enhanced apoptotic activity in tumor xenograft models when used in combination with the topoisomerase 1 inhibitor CPT-11. To investigate the cellular mechanisms involved in this increased tumor-killing activity, a series of in vitro experiments were conducted using the human colon carcinoma cell line (HCT116). Apo2L/TRAIL induced a transient upregulation of DR5 mRNA, while CPT-11 increased both death and decoy receptor expression. Upregulation of decoy receptors by CPT-11 was partially inhibited by co-administration of Apo2L/TRAIL. CPT-11 treatment resulted in accumulation of cells at G(2)M-phase and correlated with a substantial increase in the protein levels of the cyclin-dependent kinase inhibitor p21. However, cells co-treated with CPT-11 and Apo2L/TRAIL, or pretreated with CPT-11 for up to 24 h followed by 2 h Apo2L/TRAIL, resulted in a caspase-dependent degradation of p21, reversal of G(2)-M phase arrest with a concomitant increase in apoptosis. The sequential treatment produced the greatest induction of DR5 and DR4, caspase-3-like cleavage/activation and p21 degradation, as well as increased apoptosis. These data indicate that the up-regulation of Apo2L/TRAIL ligand and its death receptors as well as cleavage of p21 protein in the Apo2L/TRAIL plus CPT-11 treatment contributes to the positive cooperation between these agents in enhancing tumor cell apoptosis.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Camptotecina/farmacologia , Ciclinas/metabolismo , Glicoproteínas de Membrana/farmacologia , Neoplasias/tratamento farmacológico , Receptores do Fator de Necrose Tumoral/metabolismo , Fator de Necrose Tumoral alfa/farmacologia , Apoptose , Proteínas Reguladoras de Apoptose , Camptotecina/análogos & derivados , Camptotecina/antagonistas & inibidores , Carcinoma/tratamento farmacológico , Carcinoma/metabolismo , Carcinoma/patologia , Caspases/metabolismo , Ciclo Celular , Células Cultivadas , Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/metabolismo , Neoplasias do Colo/patologia , Inibidor de Quinase Dependente de Ciclina p21 , Sinergismo Farmacológico , Humanos , Irinotecano , Cinética , Neoplasias/metabolismo , Neoplasias/patologia , RNA Neoplásico/biossíntese , Ligante Indutor de Apoptose Relacionado a TNF , Células Tumorais Cultivadas
4.
J Med Chem ; 51(22): 7049-52, 2008 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-18942827
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA